Revance Therapeutics, Inc. Forecast, price target & analysts
Revance Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Revance Therapeutics, Inc. Classifications & Recommendation:
Revance Therapeutics, Inc. Price Target
| Target Price | $6.60 |
| Price | $3.65 |
| Potential |
80.82%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a Revance Therapeutics, Inc. price target 2026.
The average Revance Therapeutics, Inc. target price is $6.60.
This is
80.82%
register free of charge
|
|
| A rating was issued by 2 analysts: 0 Analysts recommend Revance Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Revance Therapeutics, Inc. stock has an average upside potential 2026 of
80.82%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 234.04 | 244.98 |
| 76.54% | 4.67% |
2 Analysts have issued a sales forecast Revance Therapeutics, Inc. 2024 . The average Revance Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| EV/Sales | 2.78 |
Based on analysts' sales estimates for 2024, the Revance Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Revance Therapeutics, Inc....
Current Revance Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham | Locked ➜ Locked | Locked | Jan 17 2025 |
| Barclays | Locked ➜ Locked | Locked | Dec 23 2024 |
| Mizuho | Locked ➜ Locked | Locked | Dec 10 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 08 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 08 2024 |
| Needham | Locked ➜ Locked | Locked | Oct 28 2024 |
| Barclays | Locked ➜ Locked | Locked | Sep 13 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham: Locked ➜ Locked
|
Jan 17 2025 |
|
Locked
Barclays: Locked ➜ Locked
|
Dec 23 2024 |
|
Locked
Mizuho: Locked ➜ Locked
|
Dec 10 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 08 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 08 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Oct 28 2024 |
|
Locked
Barclays: Locked ➜ Locked
|
Sep 13 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
